The OXO-001 molecule that increases embryo implantation and is already in the clinical phase, will be studied using an innovative system of synthetic matrices developed by the team of Dr. Samuel Ojosnegros in the Open Innovation Lab at IBEC.
One in seven couples in Europe suffers from fertility problems. Despite the great advances in the in vitro fertilization, the number of embryos that give rise to birth is relatively low, with a success rate of less than one in five. One of the critical factors when it comes to finding a solution to this problem, lies in the difficulty of elucidating the way in which an embryo is implanted, since this process occurs internally and techniques for its study have not yet been developed.
The laboratory of Dr. Samuel Ojosnegros at IBEC is one of the teams that has made the greatest advances in this field, developing an ingenious synthetic system, one of a kind, that allows the study of embryo implantation by using animal models.
On the other hand, Oxolife, under the scientific direction of Dr. Ignasi Canals, is developing the drug OXO-001, also the first and only one of its kind, which seeks to respond to an unmet medical need: increasing embryo implantation and pregnancy rates with a direct action on the endometrium (the uterus tissue where embryos are gestated). Currently, OXO-001 is already in the clinical phase.
This collaboration between IBEC and Oxolife will allow the availability of treatments aimed at improving embryo implantation, as well as knowledge of the implantation process at an unprecedented level of detail.
The collaboration project, which has been developed between the two entities based in the Barcelona Science Park (PCB), has received funding from the call for R&D&I Projects “Collaboration Challenges” of the State Plan for Scientific Research and Technical and Innovation 2017-2020.
For more information:
Agnès Arbat (oxolife@oxolife.com)
CEO/CMO
Oxolife
Àngels López (alopez@ibecbarcelona.eu)
Communication Department
Institute for Bioengineering of Catalonia (IBEC)
